endovascular.es

Título: TriVascular Secures $40 Million in Equity Financing
Fecha: 18-11-2013
Santa Rosa, CA, November 18, 2013 – TriVascular, Inc. today announced the close of a
$40 million Series E Preferred Stock equity financing. Existing investors New Enterprise
Associates, Delphi Ventures, MPM Capital, Kearny Venture Partners, Kaiser Permanente
Ventures and the Redmile Group were joined by new investors Deerfield Management, Rock
Springs Capital and Permal Asset Management in the transaction. Proceeds from the
financing will be used to expand commercial efforts worldwide and to fuel product pipeline
and clinical research activities.

“We are fortunate to have such strong financial support,” said Christopher G. Chavez,
Chairman and CEO of TriVascular. “We welcome our new investors to the TriVascular family
and are very grateful for the commitment of our existing investment syndicate. Our goal is to
ensure that physicians and their patients gain access to minimally invasive endovascular
aneurysm repair, which is enabled by the Ovation™ and Ovation Prime™ platforms. This
financing further strengthens our ability to continue to invest in innovation and offer clinically
compelling endovascular solutions.”

In the U.S., the prevalence of abdominal aortic aneurysms is estimated at 2 million people.
Many of these potential patients do not have access to minimally invasive, on-label
endovascular aortic repair (EVAR) given the limitations of conventional wire-and-fabric
technology. With an ultra low-profile (14F OD) delivery system and an innovative sealing
technology, the Ovation and Ovation Prime platforms are designed to expand the on-label
patient population suitable for EVAR. In October 2012, the U.S. FDA granted PMA approval
for the Ovation system. The Ovation system received CE Mark clearance in August 2010.

In August 2013, the one-year results from the Ovation pivotal study were published online
by the Journal of Vascular Surgery. In October 2013, Manish Mehta, MD, MPH, Director of
Endovascular Services for the Vascular Group in Albany, New York, presented two-year data
on the Ovation pivotal study at the annual Vascular InterVentional Advances (VIVA) meeting
in Las Vegas. The study demonstrated 100% freedom from Type I and III endoleaks,
migration, rupture or conversion to open surgical repair at both the one-year and two-year
marks. In addition, the pivotal trial cohort showed no aortic neck growth at either one or two
years. 43% of the patients in the trial were treated via a percutaneous (PEVAR) vessel
access method. Thirty-nine percent (39%) of the patients treated in the Ovation pivotal
study would have been excluded from treatment in previous EVAR trials. The Ovation
platform is approved for sale in over 30 countries. Approximately 2700 patients have been
treated with the Ovation and Ovation Prime systems to date.
Fuente: endovascular.es

endovasculares.es